AI Summary & Key Takeaways
AI InsightPost-hoc Tukey HSD test was performed for finding the different group, when the difference was detected between the groups.Results: Tenth day hsCRP levels in ezetimibe/simvastatin group was significantly lower than the other groups (p
📌 3 Key Takeaways
Abstract
Objective: The aim of our study was to evaluate the effects of two different statins and a statin/ezetimibe combination on high sensitive C-reactive protein (hsCRP) values, which were given at high doses in the early period of acute coronary syndromes. Methods: A total of 150 patients with non-ST elevation myocardial infarction and unstable angina pectoris were enrolled to our prospective, randomized, single-blind study. Patients were divided into three groups by block randomization method. One group received 20mg/day atorvastatin, one group received 10 mg/day rosuvastatin and the other group received 10 mg/day ezetimibe/simvastatin combination therapy, which was initiated within the first 24 hours of admission. Follow-up duration was 2 months . Biochemical investigations and hsCRP levels (by nephelometric method) were performed with 138 patients evaluated at baseline, 10th and 60th days of therapy. Decreases of hsCRP levels were analyzed with one-way MANOVA and repeated measures of ANOVA methods. Post-hoc Tukey HSD test was performed for finding the different group, when the difference was detected between the groups.Results: Tenth day hsCRP levels in ezetimibe/simvastatin group was significantly lower than the other groups (p
Özet
Amaç: Çalışmamızın amacı, akut koroner sendromlarda erken dönemde başlanan yüksek doz iki farklı statin ve bir statin/ezetimib kombinasyonunun hsCRP üzerine olan etkilerinin araştırılmasıdır. Yöntemler: Bu prospektif, randomize, tek-kör çalışmaya kararsız anjina pektoris ve ST segment yükselmesi olmayan miyokart enfarktüslü, blok randomizasyon yöntemi ile 3 eşit gruba bölünmüş toplam 150 hasta alındı. Acil servise başvuran hastalara ilk 24 saatte 20 mg/gün atorvastatin veya 10 mg/gün rosuvastatin veya 10 mg/gün ezetimib/simvastatin kombinasyonu başlandı. Hastaların 2 ay süre ile izlenmesi planlandı. Değerlendirme yapılan 138 hastada, 0., 10. ve 60. günlerde biyokimyasal incelemeler ve nefelometrik yöntemle, hsCRP düzeyleri bakıldı. İncelenen parametrelerdeki azalmalar, tek yönlü MANOVA ve tekrarlayan ölçümlerde ANOVA testi ile değerlendirildi ve gruplar arasında fark olduğunda farklı grubu bulmak için post-hoc Tukey HSD testi uygulandı. Bulgular: Ezetimib/simvastatin grubunda hsCRP değerleri 10. günde atorvastatin ve rosuvastatin grubuna göre istatistiksel olarak daha çok azalmaktaydı (p